SCHEMBL5196392

SCHEMBL5196392

COC(OC)c1cc(B(O)O)ccc1[N+](=O)[O-]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
CYP3A4 P08684 2/20 0.35
TSHR P16473 2/20 0.35
TXNRD1 Q16881 1/20 0.35
MAPT P10636 3/20 0.34
LMNA P02545 1/20 0.34
ENPP2 Q13822 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALOX15 P16050 1/20 0.33
PRKDC P78527 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
GPR35 Q9HC97 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
S1PR4 O95977 1/20 0.33
S1PR1 P21453 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
GFER P55789 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7141803 0.80 ALDH1A1 (0.43) ALDH1A1CYP3A4TSHRTXNRD1MAPT
SCHEMBL5197881 0.76 ALDH1A1 (0.40) ALDH1A1CYP3A4TSHRTXNRD1MAPT
SCHEMBL2928829 0.76 MAPK1 (0.53) ALDH1A1TSHRTXNRD1MAPTLMNA
SCHEMBL11287458 0.76 TDP1 (0.53) ALDH1A1CYP3A4TSHRTXNRD1MAPT
SCHEMBL4134840 0.76 CASP6 (0.58) ALDH1A1TSHRMAPTLMNACASP6
SCHEMBL4125942 0.75 VCAM1 (0.55) ALDH1A1MAPTLMNANPSR1
SCHEMBL18358659 0.74 TSHR (0.54) ALDH1A1CYP3A4TSHRMAPTKDM4E
SCHEMBL15678231 0.73 PDK1 (0.54) ALDH1A1CYP3A4TSHRENPP2ALOX15
SCHEMBL12639814 0.73 ALDH1A1 (0.51) ALDH1A1CYP3A4TSHRMAPTLMNA
SCHEMBL29462530 0.73 ALDH1A1 (0.51) ALDH1A1CYP3A4TSHRMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-1844042-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2007-10-17 EP disclosed
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses GENELABS, INC. 2006-09-21 US disclosed
WO-2006076529-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses HAVCR2, ZC3HAV1, SARS1 ALDH1A1 1627/4885CYP3A4 91/4885TSHR 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.